Transcode Therapeutics Stock News

The stock price of TransCode Therapeutics, Inc. (Nasdaq: RNAZ) increased by 4.96% this past week. This is why.

TransCode Therapeutics (NASDAQ: RNAZ ) stock is rocketing higher on Wednesday following positive study results. The big news here has to do with TTX-RIGA, which is the company's immunotherapy candidat

TransCode Therapeutics (NASDAQ: RNAZ ) stock is rallying higher on Wednesday after the company withdrew plans for a secondary offering. According to the company, it won't pursue a plan to sell 12.5 mi

BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced th

It is truly a monumental day for TransCode Therapeutics (NASDAQ: RNAZ ) stock. That's because the company just disclosed the preclinical results of its proposed treatment for pancreatic cancer.

BOSTON, May 20, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be presenting at the H.C. Wainwright Global Investment Conference. The in-person venue

TransCode Therapeutics, Inc. (RNAZ) CEO Michael Dudley on Q4 2021 Results - Earnings Call Transcript

BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be presenting at the 2022 BIO CEO & Investor Conference.

TransCode Therapeutics Inc (RNAZ) shares closed today 10.3% higher than it did at the end of yesterday. The stock is currently up 7.5% year-to-date, down 48.4% over the past 12 months, and down 48.4% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 fell 0.0%. Trading Activity Shares traded as high as $3.13 and as low as $2.39 this week.Shares closed 57.0% below its 52-week high and 28.1% above its 52-week low.Trading volume this week was 41.5% lower than the 10-day average and 24.9% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 322.8% The company's stock price performance over the past 12 months lags the peer average by 795.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

BOSTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the MedInvest Oncology Investor Conference. TransCode’s Chief Executive Officer, Michael Dudley, will describe the Company''s RNA-based scientific discoveries that it believes will significantly advance the treatment of cancer, including the company’s lead therapeutic candidate treating metastatic disease which it is advancing into the clinic with its First in Human clinical trial planned for mid-next year. The presentation will be webcast and an archived recording will be made available in the Investors’ section of the TransCode Therapeutics website.

BOSTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the MedInvest Oncology Investor Conference. TransCode'

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) was the recipient of a large drop in short interest during the month of October. As of October 29th, there was short interest totalling 185,900 shares, a drop of 22.9% from the October 14th total of 241,100 shares. Currently, 2.6% of the shares of the company are short sold. Based on []

BOSTON--(BUSINESS WIRE)--TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics, today reported recent business progress and third quarter 2021 financial results. “TransCode has made further progress across our corporate infrastructure and bourgeoning portfolio, advancing our mission to design RNA therapeutics that can effectively treat cancer. Reflecting the

These penny stocks exploded during today's trading session, are they worth watching or not? The post 5 Penny Stocks to Watch That Exploded Today, What You Need to Know appeared first on Penny Stocks t